News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx Presents Positive Results from Phase 1 Clinical Studies of Traficet-EN™ at Digestive Disease Week Meeting
Traficet-EN™ Is Well-Tolerated and Appropriate for Once-Daily Oral Dosing
View HTML
Toggle Summary ChemoCentryx Initiates Phase II Clinical Trial of Traficet-EN™ in Inflammatory Bowel Disease
Results from Phase I Clinical Studies Confirm Once-daily Dosing Regimen
View HTML
Toggle Summary ChemoCentryx Raises $33 Million in Private Financing
ChemoCentryx Raises $33 Million in Private Financing June 17, 2004; San Carlos, Calif. — ChemoCentryx, Inc. today announced that it has closed a private financing round raising gross proceeds of $33 million. HBM BioVentures and Alta Partners acted as significant new investors in the round.
View HTML
Toggle Summary ChemoCentryx and Forest Laboratories to Collaborate on The Development and Commercialization of Novel Oral Rheumatoid Arthritis and Multiple Sclerosis Therapeutics
ChemoCentryx and Forest Laboratories to Collaborate on The Development and Commercialization of Novel Oral Rheumatoid Arthritis and Multiple Sclerosis Therapeutics March 15, 2004; San Carlos, CA and New York, NY — ChemoCentryx, Inc., a privately held focused pharmaceutical company, and Forest
View HTML
Toggle Summary ChemoCentryx Begins Phase I Clinical Trial of Traficet-EN™, a Novel Drug Candidate for the Treatment of Inflammatory Bowel Disease
ChemoCentryx Establishes World-Class Clinical Advisory Board for IBD
View HTML
Toggle Summary ChemoCentryx Awarded $14 Million NIH Grant to Develop Chemokine-Based Immunomodulators
ChemoCentryx Awarded $14 Million NIH Grant to Develop Chemokine-Based Immunomodulators October 13, 2003; San Carlos, Calif. — ChemoCentryx, Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded the company
View HTML
Toggle Summary ChemoCentryx Announces Initiation of Phase I Clinical Trial of T487 by Tularik
Novel Oral Anti-inflammatory Selected from Rich Drug Portfolio Targeting Chemokine System
View HTML